# Blood samples were analysed for the presence and levels of immunity against the original strain of SARS-CoV-2, as well as the Kent (B.1.1.7), South Africa (B.1.351), Brazil (P.1) and India (B.1.617 and B.1.618) variants of concern - after infection or vaccination with AstraZeneca or Pfizer-BioNTech platforms.  Additionally, researchers focused on effects of commercially available monoclonal antibodies and their ability to recognise and destroy cells infected with coronavirus. 
